<SEC-DOCUMENT>0000950170-22-021575.txt : 20221103
<SEC-HEADER>0000950170-22-021575.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103081536
ACCESSION NUMBER:		0000950170-22-021575
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		221356366

	BUSINESS ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>gern-20221103.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-11-02T23:14:53.3466+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:gern="http://www.geron.com/20221103" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_e129bfef-e775-4996-8070-cdf5e7065b88" name="dei:AmendmentFlag" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric id="F_e8b1f013-2a9d-4a0b-815a-a489d7373168" name="dei:EntityAddressStateOrProvince" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" format="ixt-sec:stateprovnameen">California</ix:nonNumeric><ix:nonNumeric id="F_bebf6be2-3818-4ec8-bdbd-76b62ac9187c" name="dei:EntityCentralIndexKey" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34">0000886744</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="gern-20221103.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_10ec0838-cc40-4ead-8796-d3e978d94c34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">___________</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5bc622ba-1951-4c7d-8428-1b40ee2817ca" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO SECTION 13 OR 15(d) OF THE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Report (Date of earliest event reported):  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5199963f-40f1-4afb-a809-f5b46c23d646" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2022</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c819433-9bc0-43ef-8fc8-6a2e0406cdf5" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GERON CORPORATION</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.949%;"></td>
    <td style="width:28.421%;"></td>
    <td style="width:32.63%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2f4eb29f-6234-48d3-90f0-38448a5dd369" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b6e96bb2-7d89-4a2f-818b-380ab7e1bf27" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">000-20859</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a21f0009-41f1-4b8f-834f-78d8c7a16d52" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75-2287752</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_57c597e8-8f9b-4cc3-b105-9f8219b38e06" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">919 E. HILLSDALE BLVD.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f8a012db-5db5-4c5d-94e2-d86d6bf6a11a" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUITE 250</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ebe69cd5-4152-44a0-aec0-ce112fe684ca" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOSTER CITY</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e8b1f013-2a9d-4a0b-815a-a489d7373168;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CALIFORNIA</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8d267153-ceb7-47d0-84d7-3edbb6841772" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94404</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Address of principal executive offices, including zip code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d6c857c-8b68-4436-b5da-ed7cd7b811e4" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fda2eccd-55bb-4da1-8c13-93b8e578da04" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">473-7700</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N/A</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Former name or former address, if changed since last report)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_931988b3-3fe5-4ec2-bc09-8f09ffeac439" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:WrittenCommunications" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xf06f;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c377f64-77ba-4faa-a52d-c59cd51b0ec0" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:SolicitingMaterial" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xf06f;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_982e5ee7-ec53-4647-8cfe-cfc446bbd0d9" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:PreCommencementTenderOffer" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xf06f;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1a7cd9e6-3d45-460b-a92f-991f41662093" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:PreCommencementIssuerTenderOffer" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xf06f;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:32.918%;"></td>
    <td style="width:22.918%;"></td>
    <td style="width:44.165%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba1105c4-4cc0-48ca-b8b4-3f619e0f75fe" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_70b43489-0dfc-4c6e-9dfd-08c33a9dff47" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GERN</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_69cf55b1-7b52-4576-986f-0987e05b5f59" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company  </span><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_c998f739-6f09-4e44-9159-92573cc63e82" contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.02              Results of Operations and Financial Condition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Geron Corporation (the &#x201c;Company&#x201d;) is furnishing this information under Item 2.02 of Form 8-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information in this Current Report, including Exhibit 99.1, is being furnished and shall not be deemed &#x201c;filed&#x201d; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section. The information in this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 3, 2022, the Company issued a press release announcing its financial results for the three and nine months ended September 30, 2022. A copy of the press release is attached as Exhibit 99.1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01              Financial Statements and Exhibits</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d)   Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <table style="margin-left:0.5097222222222223in;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.717%;"></td>
    <td style="width:77.283%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><a href="gern-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="gern-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press release dated November 3, 2022</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                                                              GERON CORPORATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:  November 3, 2022                                         By:       </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Stephen Rosenfield</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                          </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                                                              Name:  Stephen N. Rosenfield</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                                                              Title:    Executive Vice President, Chief Legal Officer and Corporate Secretary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>gern-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><img src="img50521483_0.jpg" alt="img50521483_0.jpg" style="width:159px;height:56px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Current and Projected Financial Resources Expected to Support Planned Milestones and Operations Through</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Middle of 2024</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Conference Call Scheduled for 9:00 a.m. ET Today</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">FOSTER CITY, Calif.,</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">November 3, 2022 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the third quarter of 2022 and upcoming expected milestones.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;Throughout the year, we have highlighted our vision for Geron to become a leader in the treatment of hematologic malignancies through the expected development and commercialization of imetelstat. We continue to believe that the differentiating qualities of imetelstat, including potential for disease modification and durability of effect, could transform the treatment landscape for lower risk myelodysplastic syndromes and JAK inhibitor relapsed/refractory myelofibrosis,&#x201d; said John A. Scarlett, M.D., Geron&#x2019;s Chairman and Chief Executive Officer. &#x201c;We&#x2019;re looking forward to the IMerge Phase 3 top-line results expected in just two months that if positive, will advance the company from late-stage development to commercialization and provide meaningful value for stockholders and patients.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Upcoming Expected Milestones</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">2022</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phase 2 and non-clinical updates expected at upcoming medical meeting</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Open remaining selected clinical sites in Phase 3 IMpactMF trial evaluating imetelstat vs. best available therapy in patients with JAK inhibitor relapsed/refractory myelofibrosis </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Start Phase 2 IMpress investigator-led study of single-agent imetelstat in relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk MDS </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">2023</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Top-line results from IMerge Phase 3 in lower risk myelodysplastic syndromes (MDS) in early January </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">New Drug Application submission in lower risk MDS in the U.S. in the first half of the year</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Marketing Authorization Application submission in lower risk MDS in the EU in the second half of the year</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Preliminary data from IMproveMF Phase 1 study of imetelstat in combination with ruxolitinib in frontline myelofibrosis by year-end </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">2024</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">U.S. approval and commercial launch in lower risk MDS in the first half of the year</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">IMpactMF interim analysis</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Current and Projected Financial Resources</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of September 30, 2022, the Company had approximately $195 million in cash and marketable securities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under current planning assumptions, the Company projects its existing capital resources plus projected future proceeds of up to approximately $121 million from the potential exercise of the currently outstanding warrants and up to $50 million from the current debt facility will be sufficient to fund Geron&#x2019;s estimated level of operations, which includes stage-gated activities for potential U.S. commercial launch of imetelstat in lower risk MDS, until the middle of 2024.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Third Quarter 2022 Results</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For the third quarter of 2022, the Company reported a net loss of $41.1 million, or $0.10 per share, compared to $26.7 million, or $0.08 per share, for the comparable 2021 period. Net loss for the first nine months of 2022 was $99.3 million, or $0.26 per share, compared to $84.1 million, or $0.26 per share, for the comparable 2021 period.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Revenues for the three and nine months ended September 30, 2022, were $297,000 and $493,000, respectively, compared to $109,000 and $353,000 for the comparable 2021 periods. Revenues in both years primarily reflect estimated royalties from sales of cell-based research products from the Company&#x2019;s divested stem cell assets.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total operating expenses for the three and nine months ended September 30, 2022, were $40.2 million and $97.1 million, respectively, compared to $25.8 million and $83.4 million for the comparable 2021 periods.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development expenses for the three and nine months ended September 30, 2022, were $24.6 million and $67.3 million, respectively, compared to $18.5 million and $61.6 million for the comparable 2021 periods. The increase in research and development expenses for the three and nine months ended September 30, 2022, compared to the same periods in 2021, primarily reflects the net result of increased personnel-related expenses for additional headcount and higher consulting costs related to preparation for top-line results and regulatory submissions in lower risk MDS; partially offset by decreased manufacturing costs due to the timing of imetelstat manufacturing batches.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative expenses for the three and nine months ended September 30, 2022, were $15.6 million and $29.8 million, respectively, compared to $7.3 million and $21.8 million for the comparable 2021 periods. The increase in general and administrative expenses for the three and nine months ended September 30, 2022, compared to the same periods in 2021, primarily reflects increased costs for commercial preparatory activities; higher personnel-related expenses for additional headcount; and approximately $7.0 million for Geron&#x2019;s portion of the settlement for the class action lawsuit. In September 2022, the Company entered into a Stipulation and Agreement of Settlement (Stipulation) to resolve the class action lawsuit against the Company and certain officers of the Company. Under the terms of the Stipulation, in exchange for the release and dismissal with prejudice of all claims against the defendants in the class action lawsuit, Geron agreed to pay and/or to cause the Company&#x2019;s insurance carriers to pay a total of $24 million, comprised of approximately $17 million in cash and, at Geron&#x2019;s election, approximately $7 million in either shares of Geron common stock and/or cash. The proposed settlement does not constitute an admission of fault or wrongdoing by Geron or its officers. The proposed settlement remains subject to final approval by the court to be conducted at a hearing scheduled at the end of the first quarter of 2023 and certain other conditions, at which time payment of the settlement amount will be due.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest income was $852,000 and $1.3 million for the three and nine months ended September 30, 2022, respectively, compared to $112,000 and $421,000 for the same periods in 2021. The increase in interest income for the three and nine months ended September 30, 2022, compared to the same periods in 2021, primarily reflects a larger marketable securities portfolio with the receipt of net cash proceeds from the underwritten public offering completed in April 2022 and higher yields from recent marketable securities purchases.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest expense was $1.8 million and $4.9 million for the three and nine months ended September 30, 2022, respectively, compared to $1.1 million and $2.6 million for the same periods in 2021. The increase in interest expense for the three and nine months ended September 30, 2022, compared to the same periods in 2021,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">primarily reflects rising interest rates and increased principal debt balance. Currently, the Company has $50.0 million in principal debt outstanding.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net other expense was $138,000 and $77,000 for the three months ended September 30, 2022 and 2021, respectively. Net other income was $916,000 and $1.1 million for the nine months ended September 30, 2022 and 2021, respectively. In the second quarter of 2022, the Company recognized other income of approximately $1.3 million related to the reimbursement of certain legal expenses under its insurance policies. During the first quarter of 2021, the Company sold all of its holdings in an equity investment resulting in a net realized gain of $1.2 million, including foreign currency translation adjustments.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Projected 2022 Financial Guidance Reaffirmed</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For fiscal year 2022, under generally accepted accounting principles (GAAP), the Company continues to expect total operating expenses in the range of approximately $155 million to $165 million, which includes non-cash items such as: stock-based compensation expense, amortization of debt discounts and issuance costs as well as depreciation and amortization. The Company continues to expect non-GAAP total operating expenses for fiscal year 2022, which excludes estimated non-cash items such as: stock-based compensation expense, amortization of debt discounts and issuance costs as well as depreciation and amortization, in the range of approximately $140 million to $150 million.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The fiscal year 2022 financial guidance reflects costs to support: (a) preparatory activities for top-line results from the IMerge Phase 3 clinical trial and readiness for potential regulatory filings and commercialization of imetelstat in lower risk MDS; (b) continued conduct of IMerge and IMpactMF and commencement of new clinical studies associated with the imetelstat pipeline expansion strategy; (c) finalizing validation batches of imetelstat at contract manufacturers to enable future production of imetelstat for clinical and commercial purposes; (d) projected increases in headcount and (e) interest payments on outstanding debt.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of September 30, 2022, the Company had 98 employees. The Company plans to grow to a total of approximately 100 to 110 employees by year-end 2022.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Conference Call</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Geron will host a conference call at 9:00 a.m. ET on Thursday, November 3, 2022 to review recent events and third quarter 2022 financial results.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A live webcast of the conference call and related presentation will be available on the Company&#x2019;s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company&#x2019;s website for 30 days.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Participants may access the webcast by registering online using the following link: https://conferencingportals.com/event/SmvlMvWL%20.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About Imetelstat</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies. Data from Phase 2 clinical trials provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies resulting in malignant cell apoptosis and potential disease-modifying activity. Imetelstat has been granted Fast Track designation by the United States Food and Drug Administration for both the treatment of patients with non-del(5q) lower risk MDS who are refractory or resistant to an erythropoiesis stimulating agent and for patients with Intermediate-2 or High-risk MF whose disease has relapsed after or is refractory to janus associated kinase (JAK) inhibitor treatment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About IMerge Phase 3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">IMerge Phase 3 is a double-blind, randomized, placebo-controlled Phase 3 clinical trial with registrational intent. The trial is designed to enroll approximately 170 transfusion dependent patients with Low or Intermediate-1 risk myelodysplastic syndromes (MDS), also referred to as lower risk MDS, who have relapsed after or are refractory to prior treatment with an erythropoiesis stimulating agent (ESA). The primary endpoint is the rate of red blood cell (RBC) transfusion independence (TI) for any consecutive period of eight weeks or longer, or 8-week RBC-TI rate. Key secondary endpoints include the rate of RBC-TI lasting at least 24 weeks, or 24-week RBC-TI rate, duration of TI and the rate of hematologic improvement-erythroid (HI-E), defined as a reduction of at least four units of RBC transfusions over eight weeks compared with the prior RBC transfusion burden.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">IMerge Phase 3 is fully enrolled and patient enrollment has been closed. For additional information about IMerge Phase 3, visit ClinicalTrials.gov/NCT02598661.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About IMpactMF Phase 3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">IMpactMF is an open label, randomized, controlled Phase 3 clinical trial with registrational intent. The trial is designed to enroll approximately 320 patients with Intermediate-2 or High-risk myelofibrosis (MF) who are relapsed after or refractory to prior treatment with a JAK inhibitor, also referred to as relapsed/refractory MF. Patients will be randomized to receive either imetelstat or best available therapy. The primary endpoint is overall survival (OS). Key secondary endpoints include symptom response, spleen response, progression free survival, complete remission, partial remission, clinical improvement, duration of response, safety, pharmacokinetics, and patient reported outcomes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">IMpactMF is currently enrolling patients. For further information about IMpactMF, including enrollment criteria, locations and current status, visit ClinicalTrials.gov/NCT04576156.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About Geron</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. Geron currently has two Phase 3 pivotal clinical trials underway evaluating imetelstat in lower risk myelodysplastic syndromes (LR MDS), and in relapsed/refractory myelofibrosis (MF). To learn more, visit </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">www.geron.com</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> or follow us on </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Use of Forward-Looking Statements</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the &#x201c;safe harbor&#x201d; provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) that for IMerge Phase 3, Geron expects top-line results to be available in early January 2023; (ii) that Geron believes current and projected financial resources are expected to support planned milestones and operations through the middle of 2024; (iii) that the potential for disease modification and durability of effect with imetelstat could transform the treatment landscape for lower risk MDS and JAKi relapsed/refractory MF; (iv) that Geron expects to transform from a development stage to commercial company; (v) that Geron expects Phase 2 and preclinical updates at an upcoming medical meeting; (vi) that Geron expects to open remaining selected clinical sites in IMpactMF in 2022; (vii) that Geron expects the start of the IMpress study in 2022; (viii) that in lower risk MDS, Geron expects a New Drug Application submission in the U.S. in the first half of 2023 and a Marketing Authorization application submission in the EU in the second half of 2023; (ix) that Geron expects preliminary data from IMproveMF by year-end 2023; (x) that Geron expects U.S. approval and commercial launch in lower risk MDS in the first half of 2024;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(xi) that Geron expects the IMpactMF interim analysis in 2024; (xii) that Geron expects proceeds of up to approximately $121 million from the exercise of currently outstanding warrants and up to $50 million from the current debt facility and that such proceeds will be sufficient to fund Geron&#x2019;s estimated level of operations, which includes stage-gated activities for potential U.S. commercial launch of imetelstat in lower risk MDS, until the middle of 2024; (xiii) that Geron expects total GAAP operating expenses in 2022 to be approximately $155 to $165 million and non-GAAP operating expenses in 2022 to be approximately $140 to $150 million; (xiv) that imetelstat has the potential to demonstrate disease-modifying activity; (xv) that IMerge Phase 3 and IMpactMF have registrational intent; and (xvi) other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether the current or evolving effects of the COVID-19 pandemic and/or the Russia/Ukraine conflict cause global economic and financial disruptions that materially and adversely impact Geron&#x2019;s business and business prospects, its financial condition and the future of imetelstat; (b) whether Geron overcomes all of the potential delays and other adverse impacts caused by the current or evolving effects of the COVID-19 pandemic and/or the Russia/Ukraine conflict, and overcomes all the enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for, and to meet the expected timelines, planned milestones and events in (v) to (xi) above; (c) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (d) whether imetelstat is demonstrated to be safe and efficacious in IMerge Phase 3 and IMpactMF to enable regulatory approval; (e) whether any future efficacy or safety results may cause the benefit-risk profile of imetelstat to become unacceptable; (f) whether imetelstat actually demonstrates disease-modifying activity in patients and the ability to target the malignant stem and progenitor cells of the underlying disease; (g) that Geron may seek to raise substantial additional capital in order to complete the development and commercialization of imetelstat to meet all of the expected timelines, planned milestones and events in (v) to (xi) above; (h) whether regulatory authorities require an additional clinical trial for approval even if IMerge Phase 3 or IMpactMF meet their respective primary endpoints; (i) whether there are failures or delays in manufacturing or supplying sufficient quantities of imetelstat or other clinical trial materials in a timely manner, or at all; (j) whether the patient follow-up period of 12 months in IMerge Phase 3 results in not obtaining adequate data to demonstrate safety and efficacy, including transfusion independence, for achieving success in the primary analysis; (k) whether the FDA will approve imetelstat for lower risk MDS based on IMerge Phase 3 safety and efficacy data that is similar to the data in IMerge Phase 2: (l) whether Geron can accurately project the timing of enrollment in its clinical trials, and for IMpactMF, Geron&#x2019;s projected rates for enrollment and death events may differ from actual rates, which may cause the interim analysis to occur later than currently expected; (m) whether Geron is able to enroll its clinical trials at a pace that would enable the financial resources for, and to meet the expected timelines, planned milestones and events in (v) to (xi) above; (n) whether the outstanding warrants will be exercised and result in proceeds of up to approximately $121 million and (o) whether the clinical, regulatory and financial milestones and capitalization requirements are achieved to enable availability of the $75 million in debt tranches. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron&#x2019;s filings and periodic reports filed with the Securities and Exchange Commission under the heading &#x201c;Risk Factors&#x201d; and elsewhere in such filings and reports, including Geron&#x2019;s quarterly report on Form 10-Q for the quarter-ended June 30, 2022 and future filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Non-GAAP Financial Measure</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">To supplement Geron&#x2019;s financial results and guidance presented in accordance with GAAP, the Company is providing projected non-GAAP total operating expenses, which excludes stock-based compensation expense, amortization of debt discounts and issuance costs and depreciation and amortization, from projected GAAP total operating expenses. The Company believes this non-GAAP financial measure, when considered together with other</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">financial information prepared in accordance with GAAP, can enhance investors&#x2019; and analysts&#x2019; ability to meaningfully compare Geron&#x2019;s results from period to period and to projected forward-looking guidance, and to identify operating trends in Geron&#x2019;s business. The exclusion of non-cash items, such as stock-based compensation expense, amortization of debt discounts and issuance costs and depreciation and amortization, does not directly or immediately relate to the operational performance for the periods presented. This projected non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance projected in accordance with GAAP. Geron encourages investors to carefully consider the Company&#x2019;s results under GAAP, as well as the supplemental non-GAAP financial information, to more fully understand Geron&#x2019;s business.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial table follows.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">GERON CORPORATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(Unaudited)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42.563%;"></td>
    <td style="width:2.782%;"></td>
    <td style="width:11.119%;"></td>
    <td style="width:3.698%;"></td>
    <td style="width:11.119%;"></td>
    <td style="width:3.698%;"></td>
    <td style="width:11.119%;"></td>
    <td style="width:2.782%;"></td>
    <td style="width:11.119%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Three Months Ended</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Nine Months Ended</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">September 30,</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">September 30,</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Revenues:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:3.6pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">License fees and royalties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">297</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">109</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">493</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">353</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:3.6pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24,603</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">18,527</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">67,308</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">61,577</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:3.6pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,642</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,256</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;29,784</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;21,793</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:12.25pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40,245</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,783</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;97,092</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;83,370</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(39,948)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(25,674)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(96,599</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(83,017</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest income</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">852</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">112</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,294</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">421</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest expense</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(1,817)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(1,058)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(4,877)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(2,605)</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other income and expense, net</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(138)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(77)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;916</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,106</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(41,051)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(26,697)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(99,266)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(84,095)</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Basic and diluted net loss per share:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Net loss per share</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(0.10)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(0.08)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(0.26)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(0.26)</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;Shares used in computing net loss per share</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;405,237,474</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;328,934,491</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;380,659,049</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;326,552,763</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.213%;"></td>
    <td style="width:3.159%;"></td>
    <td style="width:15.033%;"></td>
    <td style="width:3.906%;"></td>
    <td style="width:13.688%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">September 30,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.12708333333333333in;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.12708333333333333in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">(In thousands)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(Note 1)</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Current assets:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;61,467</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;35,235</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Current marketable securities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;133,684</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;148,851</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other current assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;26,919</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;3,120</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;222,070</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;187,206</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Noncurrent marketable securities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">		</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;28,651</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Property and equipment, net</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;733</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;650</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deposits and other assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;9,803</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;9,527</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">232,606</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">226,034</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Current liabilities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;82,809</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;45,521</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Noncurrent liabilities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;41,625</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.14027777777777778in;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;54,097</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stockholders&#x2019; equity</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;108,172</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;126,416</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">232,606</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">226,034</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:-6.188%;padding-left:5.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Note 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">:	Derived from audited financial statements included in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">CONTACT:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Aron Feingold</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">VP, Investor Relations and Corporate Communications</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">investor@geron.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">media@geron.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">###</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img50521483_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img50521483_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $' A0# 2(  A$! Q$!_\0
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M $RO]VC*_P!VES[_ /CU&??_ ,>H 3*_W:,K_=I<^_\ X]1GW_\ 'J $RO\
M=HRO]VES[_\ CU&??_QZ@!,K_=HRO]VES[_^/49]_P#QZ@!,K_=HRO\ =I<^
M_P#X]1GW_P#'J $RO]VC*_W:7/O_ ./49]__ !Z@!,K_ ':,K_=I<^__ (]1
MGW_\>H 3*_W:,K_=I<^__CU&??\ \>H 3*_W:,K_ ':7/O\ ^/49]_\ QZ@!
M,K_=HRO]VES[_P#CU&??_P >H 3*_P!VC*_W:7/O_P"/49]__'J $RO]VC*_
MW:7/O_X]1GW_ /'J $RO]VC*_P!VES[_ /CU&??_ ,>H 3*_W:,K_=I<^_\
MX]1GW_\ 'J $RO\ =HRO]VES[_\ CU&??_QZ@!,K_=HRO]VES[_^/49]_P#Q
MZ@!,K_=HRO\ =I<^_P#X]1GW_P#'J $RO]VC*_W:7/O_ ./49]__ !Z@!,K_
M ':,K_=I<^__ (]1GW_\>H 3*_W:*7/O_P"/44 &/;_QVC'M_P".TW/M1GVH
M =CV_P#':,>W_CM-S[49]J '8]O_ !VC'M_X[3<^U&?:@!V/;_QVC'M_X[3<
M^U&?:@!V/;_QVC'M_P".TW/M1GVH =CV_P#':,>W_CM-S[49]J '8]O_ !VC
M'M_X[3<^U&?:@!V/;_QVC'M_X[3<^U&?:@!V/;_QVC'M_P".TW/M1GVH =CV
M_P#':,>W_CM-S[49]J '8]O_ !VC'M_X[3<^U&?:@!V/;_QVC'M_X[3<^U&?
M:@!V/;_QVC'M_P".TW/M1GVH =CV_P#':,>W_CM-S[49]J '8]O_ !VC'M_X
M[3<^U&?:@!V/;_QVC'M_X[3<^U&?:@!V/;_QVC'M_P".TW/M1GVH =CV_P#'
M:,>W_CM-S[49]J '8]O_ !VC'M_X[3<^U&?:@!V/;_QVC'M_X[3<^U&?:@!V
M/;_QVC'M_P".TW/M1GVH =CV_P#':,>W_CM-S[49]J '8]O_ !VC'M_X[3<^
MU&?:@!V/;_QVC'M_X[3<^U&?:@!V/;_QVC'M_P".TW/M1GVH =CV_P#':,>W
M_CM-S[49]J '8]O_ !VC'M_X[3<^U&?:@!V/;_QVC'M_X[3<^U&?:@!V/;_Q
MVC'M_P".TW/M1GVH =CV_P#':,>W_CM-S[49]J '8]O_ !VC'M_X[3<^U&?:
M@!V/;_QVC'M_X[3<^U&?:@!V/;_QVC'M_P".TW/M1GVH =CV_P#':*;GVHH
M=D_Y-&3_ )-''J?SHX]3^= !D_Y-&3_DT<>I_.CCU/YT &3_ )-&3_DT<>I_
M.CCU/YT &3_DT9/^31QZG\Z./4_G0 9/^31D_P"31QZG\Z./4_G0 9/^31D_
MY-''J?SHX]3^= !D_P"31D_Y-''J?SHX]3^= !D_Y-&3_DT<>I_.CCU/YT &
M3_DT9/\ DT<>I_.CCU/YT &3_DT9/^31QZG\Z./4_G0 9/\ DT9/^31QZG\Z
M./4_G0 9/^31D_Y-''J?SHX]3^= !D_Y-&3_ )-''J?SHX]3^= !D_Y-&3_D
MT<>I_.CCU/YT &3_ )-&3_DT<>I_.CCU/YT &3_DT9/^31QZG\Z./4_G0 9/
M^31D_P"31QZG\Z./4_G0 9/^31D_Y-''J?SHX]3^= !D_P"31D_Y-''J?SHX
M]3^= !D_Y-&3_DT<>I_.CCU/YT &3_DT9/\ DT<>I_.CCU/YT &3_DT9/^31
MQZG\Z./4_G0 9/\ DT9/^31QZG\Z./4_G0 9/^31D_Y-''J?SHX]3^= !D_Y
M-&3_ )-''J?SHX]3^= !D_Y-&3_DT<>I_.CCU/YT &3_ )-&3_DT<>I_.CCU
M/YT &3_DT9/^31QZG\Z./4_G0 9/^31D_P"31QZG\Z./4_G0 9/^31D_Y-''
MJ?SHX]3^= !D_P"31D_Y-''J?SHX]3^= !D_Y-&3_DT<>I_.CCU/YT &3_DT
M9/\ DT<>I_.CCU/YT &3_DT4<>I_.B@ Q[?^.T8]O_':-WO_ #HW>_\ .@ Q
M[?\ CM&/;_QVC=[_ ,Z-WO\ SH ,>W_CM&/;_P =HW>_\Z-WO_.@ Q[?^.T8
M]O\ QVC=[_SHW>_\Z #'M_X[1CV_\=HW>_\ .C=[_P Z #'M_P".T8]O_':-
MWO\ SHW>_P#.@ Q[?^.T?Y^[1N]_YTC'CK_.@ R!R3_X[0.>G_H-8?Q'\967
M@#P/J7C&_<>7I]H\VW/WF X7\3Q5GP=>:K?^%=-OM<2-;V:QB>\6/(42E 6
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M[_SH ,>W_CM&/;_QVC=[_P Z-WO_ #H ,>W_ ([1CV_\=HW>_P#.C=[_ ,Z
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MZ #J:I>&?%7ASQCH\7B'PGKUGJ5C/GR;RQN%FB?!P<,I(."".#UK\@?VU?\
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MV/OA_P"!]?\ @%XOAT>ZUK6+JWU"2?2[>Z\Q$B5E&)D8+@D] #6/_P $U?\
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MX]7Q3^W%^V+KVK^+Y/@%\)_$36=K'<+;:]JUC-B624MAH$=3E%4\,5.205X
M(/TS^U!\3;GX1_ OQ%XVT^0)>06)BL69@N)I"$5AD')4MNQCG;CWK\R?A)I?
M_"6?%_PWI&K3M*NH>(K2.Y=F)9]\Z[B3W)S7U7#N74ZT9XJJKJ"=EYVO?Y'Y
M5XB<18C"5:&58:7+*JUS-.SY6[6OY]?(^BOVYO!\WA+X@^'XMNZ-O"=K US_
M ,]9(2Z,?^^=GYTO["/Q+3P9\8%\+W]P%M/$$/V?YVX$R_,GY\K]2!WKT_\
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M*,$@%J_*7]C[]I/Q#^R;^T+X=^-^@>9)'IMXJ:I:1=;NR?Y9HNHR2A.W) W
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M3PN"0<9&'3.':OZ M#UG3?$6C6OB'1;Q;BTOK9)[69/NR1NH96'L00:_%?\
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M@[DGRH]W,L[\D]E'S,>5#?LU^S-_P3V_90_91T:WL_AA\)M-DU2-?](\3:O
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M_P >I!G&<?\ CM+CV_\ ':^/.X,^_P#X]1GW_P#'J,>W_CM&/;_QV@ S[_\
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MD;6"/(.>A%;\(XC_ (2\13A%.2]ZSZZ6M^!GC(_OH.[[?U]YWG]M_P#!8O\
MN?M$?^ .M?\ Q-']M?\ !8O^[^T1_P" .M?_ !-?O9H^K:=KFE6VL:1?175K
M=0K+;7$+[DEC895@1U!!XJU7G?ZUQO9X6'W?\ Z/J]3_ )^/[S\"?[:_X+%_
MW?VB/_ '6O\ XFC^VO\ @L7_ '?VB/\ P!UK_P")K]]B1V7]:"?[M+_6R/\
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MJT;\\>R.?SKQ_P"/WPMN/@[\8->^';PR+;V-\QL6=B=]LYW1') W':0"<8W
MUC_LS?%IO@A\<O#_ ,1II9%L[6\6/5!'GYK5_DDX')P#NQW*BOK3_@J)\(_[
M0TK1?CKX>LUEC7;8ZM<6\>[]VW,,K$#[N<IN) RR ?>K[*%26#SRS^&JK?\
M;R_K\3\S\3<G_M+A_P"LP5Y4'?\ [=>_W:/Y'J/_  3C\>MXQ_9JLM-GDDDF
MT&_FTZ0LH P-LB!?4".1!GU!KY^_;;\)_P#"*_M!:I/&BK#JT,-]&J+T)78W
MU)9&8_[U2?\ !+7XC?\ "/\ Q;U;X=7)_=^(M-66']V2?.M]S#GH!LDDSZD+
M7HO_  4G\.A+[PWXJ";?,CFMFXZXPPK^>OI 9+&60UZB7\.<9KT;L_Q9^O?1
MWX@>*^K)O5QE3DO.*NOP2?S/EX=*^COV+8=#^,'PQ\=?LS^-U:;2]:TV0-&
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M(P592,$$=C7SV4YI5RG%JM'5;-=&O\SHJT8UH<K/QV_X)F?\%G;S]G'PW9_
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MD/+,<=.%'10HXKTAA@=/TKYO.,9A<9BG/#4^2-K+SMU?8ZZ<90I^\[L_-?\
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MYO6C<WK1M^OY4;?K^5 !N;UHW-ZT;?K^5&WZ_E0 ;F]:-S>M&WZ_E1M^OY4
M&YO6BC;]?RHH ./;]:./;]:7=[?K1N]OUH 3CV_6CCV_6EW>WZT;O;]: $X]
MOUHX]OUI=WM^M&[V_6@!./;]:./;]:7=[?K1N]OUH 3CV_6CCV_6EW>WZT;O
M;]: $X]OUKE/C1\)]!^-?PTU;X:^) OV?5+;8)-N3#(#N20>ZL ?PKK-WM^M
M(6R,8_6JIRE3DI1T: _&3XI_#/Q3\'_'NH_#KQG8/;WFFW!C;<IVRIGY9%]5
M9<$&ON?]B7QSI/[4_P"R7JWP!\83QR7VC6']G-YF-WV<KFVE'7E"H ..#&O!
M-=E^WA^R#:?M%^"?^$G\*6JIXMT6!CI[@@?;(NIMV)XY.2I/1CZ$U\/?L??&
M#6OV<_VCM-U#5XYK6UFNVTGQ)9SQE62)WVMO4C(:.0*^, Y0KP":^VEB(YQE
MO-#2I"S^:ZKR9RUJ,*M.5.HKQDFGZ,L?";4=<^!G[1NCOK")#=:+XB2VO@TC
M(H'F>6Y)X.W!)Y[=:^RO^"C5JEW\,]#U)""(]4.P@]0T?_UJ\$_X*8?"NW\%
M?&JU\>Z; D=GXKLS*=F /M,.U9> .A5HFR<DLS>E>Q?MV>(X=1^"'@F2W;:N
MH;+A5;KM\@$?^A5^;^-5:GBN *N+?VH6?KS+]3P/ 3"XC*>/*N5-_P .HI+T
M<7K\U8^4^>N:^C?^"<7A6>_\?ZUXNDA7R;#3U@5R.DDC9Q^2G\Q7SK:6EUJ-
MW'I^GV[2S32".&)!EG8G  '>OMKPS\(/&WP<_91O?!/PW01^-->LWBAON<6M
M]<+L6=B%;"P*0W3!\O'5J_E3P=X?K9OQ53Q37[NA[S?3F>B7XW^1_7/B5G%+
M+^'Y89/WZVB7DG=O\+?,^1_^";WPME_:7_X*=_%_]N._E2]T'P_XEU*Q\)ZA
M'\T5W(Y:VBEC;/(6S4=B#YP.017Z8 8XKS[]ES]G3P'^RI\$]#^"GP^M=MGI
M-J!<73#$E[<L,RW$G)^9WRV,X484850!Z'N]OUK^S,TQGU[%<R^&*48^B7Z[
MG\UTH<D+/U&DJO?^=>8_$3]M+]E'X2>*KCP1\3?C]X7T/6+55:XT[4M42.:,
M,,J2I/&17ISG=\H_G7XI?\%^?A9K7@_]LNW^(<EAMTWQ1X<MWM9XXVVM+"3'
M(I/3=]TXST*^HK?(\NHYICO85).-TVFK;KI]Q&(J2I4N:)^S?A'Q=X8\>^&;
M'QEX-URWU+2M2MUN+#4+20/%/$PRKJ1U!'>M(8SUKXU_X(I?M6^#?CC^R/HW
MPI.K6T?BGP#:KIVHZ6K%9#9J2+>Y4$G<K)A6(X#J00,KG[*5QG KAQV%J8/%
M3HS7PNWKV9=.I[2"EW#'O2,#V(I^[V_6FNPQC^M<IH?*W_!6G]CGP1^TY^RS
MXB\2OI*+XM\&Z/<:KX<U2.WWS'R5,KVIP1N2559<$D*S*X!(P?S(_P""*_QP
MUCX1?MU>'?#UM=3_ -F^-$?1M2M(6^20LI:%V'^Q(H(/4 L!U.?UD_X*5_M(
M^%?V:?V0/&'BG6M8CM]2U71[C2O#=OPTEQ?SQ,D8"]U7.]CT"H>^ ?R!_P""
M0'PSUOXE_M_>!6T>*3RM!NI-7OI5B9ECAAC/WB/NAF*J">,L!U(K[[(95*G#
M>)C6^!)VOZ7T^?XGFXCW<1#EW>Y^_*D8XQ2T @<8IV[V_6O@O,](:<4#KDBG
M;O;]:-WM^M(!O?I0:=N]OUHW>WZT -  H/3@BG;O;]:-WM^M%@&@8[T#WIV[
MV_6C=[?K0 G'M^M''M^M+N]OUHW>WZT )Q[?K2<4[=[?K1N]OUH :?;%&.,$
MBG;O;]:-WM^M&P#>,T<>E.W>WZT;O;]:+L!OXT8&,4[=[?K1N]OUH#8;S[48
MYYIV[V_6C=[?K0 WGVH&/;]:=N]OUHW>WZT (?;%)R.].W>WZT;O;]: &XYZ
MT4[=[?K1N]OUH : !Z4O'M^M+N]OUHW>WZT )Q[?K1Q[?K2[O;]:-WM^M "<
M>WZT<>WZTN[V_6C=[?K0 G'M^M''M^M+N]OUHW>WZT )Q[?K1Q[?K2[O;]:-
MWM^M "<>WZT4N[V_6B@ X]3^=''J?SH_X#_X[1_P'_QV@ X]3^=''J?SH_X#
M_P".T?\  ?\ QV@ X]3^=''J?SH_X#_X[1_P'_QV@ X]3^=''J?SH_X#_P".
MT?\  ?\ QV@ X]3^=''J?SH_X#_X[1_P'_QV@ X]3^=!Z<$_G1_P'_QVC_@/
M_CM #3TZU\8_\%,OV1%UG3KC]HWX>:=_IEFJ_P#"26=O#_KH1Q]I&!U08W?[
M(S_":^T",C!7_P =JOJ.GV6I6,VGZA:K-#/&T<L4BY5U/!!]C77@<74P6(56
M/3==UV$XW5CXV_:$@G^-7_!/WP+X_9Q-J5G)8JL=O'N::1Q]F,8/7))!P.I4
M5E?MR>(X;GQIH/PXTI/D\/Z)#%)#'GY)'5<)C'!"A?\ OJOI3PW\ O"?P]^#
M'_"M)-*DUC3])U2;4M+LO,*L7%RUQ!'D8^ZQ4=,<=ZYOX(?LJ_V5XLN?C%\8
MI8=2\37]VUT+?&Z&R9CG S]YAT'90,#.,U\+XE87,.*,MI9'@5:,YN4YOX8P
M332\VWT/8X&AE_#O$>(X@Q&K<(QC%;REKKY))[G,_L<?LF-X7^S_ !6^)5A_
MQ,6CWZ5I\R_\>V>DC _QXZ _=SV/3Z96-, YH5 JX"_I3QT^[_X[7H<.<.Y=
MPSED<'A%HM6^LGU;?]6)SK.,9GV/EBL2[MZ)=$NB0@&#UI>/4_G1_P !_P#'
M:/\ @/\ X[7OGE#6Z]:\%_X*&?L.>$/VZO@A)X U.YCT_P 0:9(;OPMK;0AC
M9W.W!1N-QAD&%=01G"MR46O?"<?P_P#CM-('WMOZ5MAZ]7"UXU:;LT]&3*,9
MQY6?SAW=A^U'_P $\_V@@TJ:IX/\8:%<,L,ZK^ZNH\X)4GY;B!QCU!![&ONK
MX#?\'%UW86-KI7[2/P.DO)(U5;C6O"MTJLV%Y<V\V%+%NPD4#MG%?H[\;/V=
M?@G^T7X8/A'XT_#C3?$%F%80K?6X,D!;JT;C#1G@<J1R!Z"OBOXQ?\&[W[-/
MBZ:>_P#@S\5/$W@VXFF4I:WB1ZI9PH!@JJ-Y<V3R<M,V">., ?;?VYD>;P2S
M&G::TYE?\UK^#.'ZO7HW]D].QK_\1$/[$V/^2??$S=_=_L2Q_P#DVO.?C!_P
M<<>$8X)+3X#?L_ZE<R[08;[Q5?)"H.>088"Y/'0B3KVK);_@VLN?X?VSEV_]
MD[/_ ,L*[WX1?\&Z_P"SOX8ECO/C+\:/$WBV6.X#K;:7;Q:5:RQX_P!7(N9I
M3]4E0_2L^7@NC[Z<I6Z:_P"2_,/^%"6FB^X_.#XM_'/]K+_@HE\7K-/$DFI^
M+-<F/DZ-H&CVC&&V!ZB&%<A1QEF//')P!C]>_P#@E/\ \$X[+]A[X;W7B3QS
M]GO/'WB:&/\ MJZAVNEA"/F%G$_4KN(+L#AV53R$6O;O@!^R7^SS^S#HO]B?
M!+X6Z9H8:/RYKN&'?<SCC_63.2[]!U8]!7HZ+@8*_I7FYQQ!]=P_U7#0Y*7;
MJ_\ )&M'"^SES3=V.  '.:./4_G1_P !_P#':/\ @/\ X[7S)UAQZG\Z./4_
MG1_P'_QVC_@/_CM !QZG\Z./4_G1_P !_P#':/\ @/\ X[0 <>I_.CCU/YT?
M\!_\=H_X#_X[0 <>I_.CCU/YT?\  ?\ QVC_ (#_ ..T ''J?SHX]3^='_ ?
M_':/^ _^.T ''J?SHX]3^='_  '_ ,=H_P" _P#CM !QZG\Z./4_G1_P'_QV
MC_@/_CM !QZG\Z./4_G1_P !_P#':/\ @/\ X[0 <>I_.CCU/YT?\!_\=H_X
M#_X[0 <>I_.CCU/YT?\  ?\ QVC_ (#_ ..T ''J?SHX]3^='_ ?_':/^ _^
M.T ''J?SHX]3^='_  '_ ,=H_P" _P#CM !QZG\Z./4_G1_P'_QVC_@/_CM
M!QZG\Z./4_G1_P !_P#':/\ @/\ X[0 <>I_.CCU/YT?\!_\=H_X#_X[0 <>
MI_.CCU/YT?\  ?\ QVC_ (#_ ..T ''J?SHX]3^='_ ?_':/^ _^.T ''J?S
MHX]3^='_  '_ ,=H_P" _P#CM !QZG\Z*/\ @/\ X[10 ;O?^=&[W_G1_P "
M_P#'J/\ @7_CU !N]_YT;O?^='_ O_'J/^!?^/4 &[W_ )T;O?\ G1_P+_QZ
MC_@7_CU !N]_YT;O?^='_ O_ !ZC_@7_ (]0 ;O?^=&[W_G1_P "_P#'J/\
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MW_G1_P "_P#'J/\ @7_CU !N]_YT;O?^='_ O_'J/^!?^/4 &[W_ )T;O?\
MG1_P+_QZC_@7_CU !N]_YT;O?^='_ O_ !ZC_@7_ (]0 ;O?^=&[W_G1_P "
M_P#'J/\ @7_CU !N]_YT;O?^='_ O_'J/^!?^/4 &[W_ )T;O?\ G1_P+_QZ
MC_@7_CU !N]_YT;O?^='_ O_ !ZC_@7_ (]0 ;O?^=&[W_G1_P "_P#'J/\
M@7_CU !N]_YT;O?^='_ O_'J/^!?^/4 &[W_ )T;O?\ G1_P+_QZC_@7_CU
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M\J3!_NT8/]V@!<#T/Y48'H?RI,'^[1@_W: %P/0_E1@>A_*DP?[M&#_=H 7
M]#^5&!Z'\J3!_NT8/]V@!<#T/Y48'H?RI,'^[1@_W: %P/0_E1@>A_*DP?[M
M&#_=H 7 ]#^5&!Z'\J3!_NT8/]V@!<#T/Y48'H?RI,'^[1@_W: %P/0_E1@>
MA_*DP?[M&#_=H 7 ]#^5&!Z'\J3!_NT8/]V@!<#T/Y48'H?RI,'^[1@_W: %
MP/0_E1@>A_*DP?[M&#_=H 7 ]#^5&!Z'\J3!_NT8/]V@!<#T/Y48'H?RI,'^
M[1@_W: %P/0_E1@>A_*DP?[M&#_=H 7 ]#^5&!Z'\J3!_NT8/]V@!<#T/Y48
M'H?RI,'^[1@_W: %P/0_E1@>A_*DP?[M&#_=H 7 ]#^5&!Z'\J3!_NT8/]V@
M!<#T/Y44F#_=HH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C
M=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1
MA:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=
M]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A
M:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]
M?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:
M-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?
MSH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-
MWU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?S
MH ,+1A:-WU_.C=]?SH ,+1A:-WU_.C=]?SH ,+11N^OYT4 +CV_\=HQ[?^.T
MF%_O487^]0 N/;_QVC'M_P".TF%_O487^]0 N/;_ ,=HQ[?^.TF%_O487^]0
M N/;_P =HQ[?^.TF%_O487^]0 N/;_QVC'M_X[287^]1A?[U "X]O_':,>W_
M ([287^]1A?[U "X]O\ QVC'M_X[287^]1A?[U "X]O_ !VC'M_X[287^]1A
M?[U "X]O_':,>W_CM)A?[U&%_O4 +CV_\=HQ[?\ CM)A?[U&%_O4 +CV_P#'
M:,>W_CM)A?[U&%_O4 +CV_\ ':,>W_CM)A?[U&%_O4 +CV_\=HQ[?^.TF%_O
M487^]0 N/;_QVC'M_P".TF%_O487^]0 N/;_ ,=HQ[?^.TF%_O487^]0 N/;
M_P =HQ[?^.TF%_O487^]0 N/;_QVC'M_X[287^]1A?[U "X]O_':,>W_ ([2
M87^]1A?[U "X]O\ QVC'M_X[287^]1A?[U "X]O_ !VC'M_X[287^]1A?[U
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M*** #(]?THR/7]*** #(]?THR/7]*** #(]?THR/7]*** #(]?THR/7]***
M#(]?THR/7]*** #(]?THR/7]*** #(]?THR/7]*** #(]?THR/7]*** #(]?
MTHR/7]*** #(]?THR/7]*** #(]?THR/7]*** #(]?THR/7]*** #(]?THR/
M7]*** #(]?THR/7]*** #(]?THR/7]*** #(]?THR/7]*** #(]?THR/7]**
6* #(]?THR/7]*** #(]?THHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>gern-20221103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-11-02T23:14:53.3339+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.geron.com/20221103" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:gern="http://www.geron.com/20221103" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gern-20221103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gern-20221103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.geron.com/20221103/taxonomy/role/Cover" id="Cover">
        <link:definition>100000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>gern-20221103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-11-02T23:14:53.4321+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>gern-20221103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-11-02T23:14:53.2911+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.geron.com/20221103/taxonomy/role/Cover" xlink:href="gern-20221103.xsd#Cover" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.geron.com/20221103/taxonomy/role/Cover" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139828921697392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  03,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-20859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GERON CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-2287752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">919 E. HILLSDALE BLVD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">FOSTER CITY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">473-7700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GERN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>gern-20221103_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gern-20221103.xsd" xlink:type="simple"/>
    <context id="C_10ec0838-cc40-4ead-8796-d3e978d94c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_e129bfef-e775-4996-8070-cdf5e7065b88">false</dei:AmendmentFlag>
    <dei:EntityAddressStateOrProvince
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_e8b1f013-2a9d-4a0b-815a-a489d7373168">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityCentralIndexKey
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_bebf6be2-3818-4ec8-bdbd-76b62ac9187c">0000886744</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_5bc622ba-1951-4c7d-8428-1b40ee2817ca">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_5199963f-40f1-4afb-a809-f5b46c23d646">2022-11-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_1c819433-9bc0-43ef-8fc8-6a2e0406cdf5">GERON CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_2f4eb29f-6234-48d3-90f0-38448a5dd369">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_b6e96bb2-7d89-4a2f-818b-380ab7e1bf27">000-20859</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_a21f0009-41f1-4b8f-834f-78d8c7a16d52">75-2287752</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_57c597e8-8f9b-4cc3-b105-9f8219b38e06">919 E. HILLSDALE BLVD.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_f8a012db-5db5-4c5d-94e2-d86d6bf6a11a">SUITE 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_ebe69cd5-4152-44a0-aec0-ce112fe684ca">FOSTER CITY</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_8d267153-ceb7-47d0-84d7-3edbb6841772">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_7d6c857c-8b68-4436-b5da-ed7cd7b811e4">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_fda2eccd-55bb-4da1-8c13-93b8e578da04">473-7700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_931988b3-3fe5-4ec2-bc09-8f09ffeac439">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_7c377f64-77ba-4faa-a52d-c59cd51b0ec0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_982e5ee7-ec53-4647-8cfe-cfc446bbd0d9">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_1a7cd9e6-3d45-460b-a92f-991f41662093">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_ba1105c4-4cc0-48ca-b8b4-3f619e0f75fe">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_70b43489-0dfc-4c6e-9dfd-08c33a9dff47">GERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_69cf55b1-7b52-4576-986f-0987e05b5f59">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_10ec0838-cc40-4ead-8796-d3e978d94c34"
      id="F_c998f739-6f09-4e44-9159-92573cc63e82">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MLB#A"$<SYVC>EHP%5T+Z9!SY!(JO-"^X4E9&61U5%5(K9VNABN-("_U*GD7
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( /%!8U6JQ"(6,P$  "("   /
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M              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /%!8U4D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( /%!8U5ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="gern-20221103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20221103/taxonomy/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince -  gern-20221103.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="gern-20221103.htm">gern-20221103.htm</File>
    <File>gern-20221103.xsd</File>
    <File>gern-20221103_lab.xml</File>
    <File>gern-20221103_pre.xml</File>
    <File>gern-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gern-20221103.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "gern-20221103.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gern-20221103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gern-20221103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gern-20221103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "gern",
   "nsuri": "http://www.geron.com/20221103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "gern-20221103.htm",
      "contextRef": "C_10ec0838-cc40-4ead-8796-d3e978d94c34",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Cover",
     "role": "http://www.geron.com/20221103/taxonomy/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "gern-20221103.htm",
      "contextRef": "C_10ec0838-cc40-4ead-8796-d3e978d94c34",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.geron.com/20221103/taxonomy/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000950170-22-021575-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-021575-xbrl.zip
M4$L#!!0    ( /%!8U7'AVJQ[!(  !',   1    9V5R;BTR,#(R,3$P,RYH
M=&WM/6M3XSBVW^=7Z+)WIZ N2OQ^!)HM)H2>U-! )?3NW/NE2Y:.B;<=.V,[
M0/;7WR,Y#@F/@6D('=-.5S6)??0Z.F\=2?O_N!G'Y JR/$J3#UMZ2]LBD/!4
M1,GEAZW#8;??W_K'P?Y_44J.CONGY!2NR2$OHBLXBG(>I_DT [(]_+1#^DD<
M)4!^_V5P0HY2/AU#4A!*1D4QZ;3;U]?7+1%&29[&TP*;REL\';<)I67=W0R8
M?$R.6 &D8VB&076=:L:%879TJV.;+=-RG/_1M(ZFW99*)[,LNAP59)OO$%D(
M6TX2B.,9.8X2EO"(Q618-;F+?>0M<AC'9"!+Y60 .617(%JRRI_V1P7B O&1
MY!^VEOI];;;2[+*M^[[?OI$P6R50YR;(8A$M8.5/!6EHFM,N7ZZ %@^"VB5H
ML0P:K71@&=IL(Q(+'!I4\(CVKW\"+E\'+%^ W]R#7QF??%N!1C>/U:O+;LCY
MEM-=@2=I<HK3GD7\X6*BR-K%; )M!*1)"7G;5/%PH=MFVD7&DCQ,L[$B%=D+
M&RF$&LY2)32'U=;Q=^LRO7JR'H^:^@)%>?00@A"=>OOW3R=#/H(QHW?G0< =
M4JB:QA=M29R+;N:I9>CNGTUQ"5$5N(0L68'&!VFB.$C6J^N:68%.B^S1>OTV
MOMTZ^(GLCX )_$OVBZB(X<"CO^VWRZ_RX1@*IOB6PA_3Z.K#5C=-"N1F>H&3
MMT5X^>O#5@$W1;ODA[:LM3VO=C](Q4S5)*(KDA>S&#YLB2B?Q&PFB03VM@[V
MHYN.!(>L_!H) 8GZ>DM%)!(?MHZ_@&[X00@A!=>UJ>7[#O4T5Z-<A#:XFF,'
MGK=%$C:6K4#4.43)(Z3T.8[9Y;R[-\4 0AS(%UT#KGFF1SFW-&IA#ZCG8HW"
M!-_UA&]QT]HB)7%\V$*"Z@1I&@-+0A8C#QVH/_OME7X^TFTOT$-D%&HP7U"+
M:0'U=)M19GF^<$W7U)V5;O<2G('9H1 9Y/FP0#EXEIUGZ56D2.R%HY!LT<EE
MI1.L4C8*R=9!E\41 B41>]:( @A")P"#FI[N8:O<HX$(!'6=P#$8]W7/Y?='
MU,69R%C<3P3<_ :S;QK*@88?SW-<R[K7T_8J^6000H8:#/*#?2G+.KGB5FR-
M*-G6D1+HPU8>C2>Q9%WU;)3)SD@VHQ5#M6YR@63:7JVC;&ZY#?4S3Z>9^J5D
M=V<^0H6VYXYP7A04SJI?D9"_PP@RHKH #XJV;O^W50S=+7Q0/5JM?8((3$7U
M"ZDC*Z3Z/5AH7[,J=_MNT4WQ"&CUIOI=-=)>04V%QP7BVDORH(UB0XF/224\
M9!&4MW) ':VE_7TOQ&IH'OT'.CK^GA1[8Y9=1@DMTDFG?""E/1V!U/,=O:7;
M99&0C:-XUKF(QI K6V:0CEE2E0[2HDC'\PI4F\@@ETF'8[N02:F53UA2=2I@
M_.MEEDX307D:IUDGNPS8MK:K_NWLW7NF[^Q=CZ("*%;"H3/)@%YG;%)V[+KL
M:9#&XO[@EKO^\Q_3M-B[,X#RX2Y!:R8*]\8XE.M(%*-.&!5T+JZQ]Y]/^Q>]
M(S*\.+SH#??;<BR([$F#ZM='];#7_3SH7_1[0W)X>D1ZOW=_/3S]V"/=LT^?
M^L-A_^RTP?\Z\?^OP^&O_=./%V>GN^2HU6VA<V!;?H/S=>+\R^VG5HC^)DPF
MTK:*UX9+,L?@SW_3'6VO'GBL'<$>GPT^58A>&<E+&]QZV'ZV ^X81L"H[MLZ
MM;B+AJ!E>%0/+ W \'27LV^S]&]M[BKRHERUFL^/<DOG@N2NT=_(ET:^;#K]
MH@DXZ)U>D$'O_&QP\9"@V;P^DUJQ5NU(XOSS8/CY$&GBXHR@CW"!C@#137(V
M(+J]+7;(V3&Y^+77D$I#*LLNY,)]/.Q>2!+1?=.J%?(;%;BY1+QF-*L%O30D
M YBD64&VJ]_ LCB"O"!P)1<*,_4:Q$Z'O*E)+A>]'#.DEA:B2<["@#)/\VEH
M!Y;##5,XEO-:)OFYBH3VROCHZAJ#P"=C;&0DV&R&F)'!^7I+K]/T"L8!9,1\
M:#9K-YQ=M;K\PWHC;V)'U$D0KTD<Z=S3?<LTJ1]P%"TFA-0+N4<=9H!F:8Y<
M\GRI."I7Y09P&>5R(;PXQ3=UES8?>P,TI+MG W2T#B^6H^LUYM0:*OOMW@WC
MA2(VJ>.S!9$1EI-\ EPN1PH2)20J<L)'#%5^ME.K6=E$M#\L00L6Q+ @IC03
MD*D^1LEE1]M3;VG,9NFTP.IN0.R55?NV1/4<'D<;LTD.G1PF+$,K94_FC\C*
MLZKFJRB/@BA&F=*IH.= ""4JJ+)NTVOYEO]WB=-V(1X!,KR69>A/ )E&RS%7
M8/!+=K=O%264V+[?JR=8[!J10(,,V->.^I_*!P_/]H0)F3)'8P@5L7I1LG<%
M61%Q%L_I":ET ::RUBJX)9J3Q>6@'N.!BF;^ A-H]5%_1FA!8/@A=0S3HI8G
M4!%JH49-S[(\9@MA.O[KJ+]^PM,,/0Z5 ::2;;I(!44VZZ8"GI$Y4V]U>00Q
MNT8OXVDM^2 '-ERS45P3.. [06!05W@^^K &&HVZ%R#7:"QP00]"PWT=KCF.
M8L"VT:VK.P=HFD8-S;/]A@7> PLP0P]Q2I'Z=1G&"3QD =,**9*RQUVF.\(V
M7H<%+MA-?YY7QY7R>!_\X-K4,#S7M9\1XV@LKN_ .'5T!I5=1=*,I,4(,O+O
M:1;E(N)JGP=ZA]&R#;;32-R&<"K"Z:;C<93+'4E$FARDE+$-B30DLB"1_F!(
M>N-)G,Y0LJQJ9'*:MAZDE4I?X5\9_&B"34VX_H6KARZW?1<\ZH5^0"W.31KH
MFDW]T#-T/S ]T%Z\>KBR+6C^YP01IM?=Y/1UG_1:Y-?^R<GPZ/"D1WXY^>=1
MZPGSL]8CWGW+E>W08YINB(#:(K"1-FU!?0L,*CQ'.$'H,%U_<;+I8[1IU)TV
MAY_[%SUBV-I[6$=:$X%! ([/!=*6;AO4LIA&&9(/Y:#K1@B.9[T\FWF%P+KX
M]2R[2*]K'W\]/AM>] :DV[_XWT;>?0,Y+E<GX_,TNJ'E%M#.\_;=UCXYL'MX
MTC\^&YSV#Q<$M/*GUH-[2S7I"<-Q==M$L16XU'*%1CU+N-0$$00HPW37?:7(
MX5R*G:=YP>+_BR9JI:GF,^5;EF:]!QVY>:BMHYM5PT "V9[SI8Q(3K(HX=&$
MQ01N@$_E*3?X.(PXY+LR7!E/9;B'_">:H$00T"2N-$1> R&]_8;JU!4.]VR7
M4P^5)SH%ID,#6S *PN7"#3Q=!^NEZE3Z 8<9L/>@0)TG7<Q:#V_G32,>@AG
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MH2MELT_!WD(U@M;:U9+Z$NC_!5!+ P04    " #Q06-5N8A=^=T%   G-
M%0   &=E<FXM,C R,C$Q,#-?;&%B+GAM;,U;VV[C-A!]SU=,W9<$C2Q+WC[$
M2+)PG:0PFAMB+[IH42QDB;:%E4F#DF]_7U*W6!(I)78HY2FR-#P\O,UP#B:7
M7[<+#]:(^B[!5RVCW6D!PC9Q7#R[:GT;:?W18#AL?;T^N?Q%T^#F;O@(CV@#
M?3MPU^C&]6V/^"N*X'3T< ;?_WBYAWL7_YQ8/H(;8J\6" >@P3P(ECU=WVPV
M;6?J8I]XJX!UZ+=MLM!!TV+X 446?P\W5H"@9W9,4S,,K6..S6[/^-+[O=O^
MTC6-WSJ=7J>SUXPL=]2=S0,XM<^ MV)]8XP\;P=W+K:P[5H>C)).SV&([3;T
M/0]>>"L?7I"/Z!HY[0C38R/H><DPMK[;\^TY6ECWQ [I7;7VQK.=4*]-Z$PW
M.YVNGK:26O!?6F*F\5>:86I=H[WUG1:PU<!^V/<;.DG,MP7[33>T-BXN+O3P
M:VKJNR)#!FOHWQ_N1^$X-;9" 9LUU+H^ 8BGPYH@CR\MA'@]2CQ40I%_UN..
M0_O #7B#%"9]OUNRUV@;(.P@)^PP[9+8&2./3S^A2<LY1=.(@<\HA-W[R&[/
MR%IWD*OS;< ?-/[ )_=7]N/'+69$=GW'H<CW!^SQB8[)!B>8(;VK5IFEKIHB
MVZ>N[0;L #ZP4T#9UA6P$Q@I)]9GA]GA!_K.LV8"3MGORNE$"\2.,J%+0L.#
M.0K89 S("@=T-R .DBYK>2OEU/EVZC-?)^&8^:R<3.*FG]DV(LXM=KCS%; 2
MV]6TS/$Y?";,,7G_N,O2U14:UT3TSO70XVHQ051*;\^DWMF+_S#WBXRJR<O8
MUD1S;&V'#MMA[M2- FW%1,KL:Z)[NT!TQCSPGY1L@OF +)86WDG)BJUKHOJ"
M9JX?4 L'C]9"?G!R9LK)/5/F=Q?,J=B(>Y8QOP/0I^E4N.8EQNIC,K)7E$V0
M84[&_"(CBLAYDWK/=AC$GN@S)6N7W]PJCG?>O+8H,V:()<$E_*R<S-]LH=B%
MDV^G%8Y]AR]@);:K;;?=;NVYA6=(<F:%9HU%%/,=$<6LB^: ;2EJ>4/F*K9_
M(;ESSMLII\=32>]Y3K#\LE PJ=L=#WU_A>B[G'*QB?J[-%DCVI_PL&4'HLMT
MYKMR.F-J<>UDM%M,B"AQRW[/TN%6/$]G3UQ]05C[-LKFR>P D16M=N^O^>H/
M;Y+2>%/.SA%;UQ$:Q'#GP &!4."0E_IKWQ_'OYC1'DC]%0@2)#6,,_GN@613
M#. @:GB^(>4];I=DH,\A!.>;)>X > ]JAK:?*1\XAG!G<PR%-(6I\X%\4U4U
M @.&%LJE*O>.**'^(,<280(#53C_^;S[..X<!R*@&B9]/Q'_H#F/'[A2C^ )
M*YUT28Y^W$@8*&11:U@/80)_W#@22(@P(095.8ILBG\<_5<LX&!J:,O3_@/)
M,T#-WD.$"!)"3$5WFYPV<"#SL"V0*1CFZ>0,$M0:G%!.+O@@/Y1>%!)<M=&7
M:PO'!EV.H8:E4&LXD&Z,!5DPM7M[7X4X].8>0T&"I="M2*4)%3%VO"$J1Y%3
M+XX;00P&(1HP.#7,\^K&@:1#& AQE%X!JG2.CXI%$7 -(2DCBQR:.G$,^#=!
M^4\-TXQB<FCDC# @ BGEV:=94<BB=M(A>ZSH,[;0;<(6=!EH4?=Q\RDEB_+:
M@J1C4BWI%)6C.HC+:Q,2SA(9IQFZPHJ%A&E1OFF&Y#OJ&+(;HUK1:69 HNJ&
MA'E!L&F&8FG-0\)5KMHTN5'**B&$CJ.HVC1)OU@?D26=$VD^P4R+JB:$$UU0
M:IHD7U%+D1U F4C3Y"!**RRR0Y"K,TT.0%QWD64N4&2:H5Q=C9$0K]!D&KJ;
M2&HTTIN)2(3Y!/Y%4KDA=#$B':;9"+I?SY$/G*G@T@S%TBJ/A*M<=FEV%XMJ
M/_([N2"Y?(+=+*H(J8J69N/D)74B6>(BF:49TK+JD82O4%SY%$%%6E,B"2UB
MH:6AO$94:9(F-@4]I1F2POJ3A&112@E)[NLA[#S^O#Y)WKC1/YI<_P]02P,$
M%     @ \4%C55_U! F)!   4"H  !4   !G97)N+3(P,C(Q,3 S7W!R92YX
M;6SMFF&/VC88Q]_?I_"R-ZVV$!+:;H>.JQAW5Z%R=PBH5NW-%!(#5AT[L@.$
M;[_'N;@EQ(%54[))V9LCX+_MG_]VDN=Y=#?OTXBB'1:2<#:PW$[70I@%/"1L
M/; ^S>WA?#0>6^]OKVY^L&UT]S!^0D]XCX9!0G;XCLB <KD5&+V:/[Y&GW^;
M3="$L"]+7V)TQX-MA%F";+1)DKCO./O]OA.N").<;A.84'8"'CG(MO/A1P+[
MZG=TYR<8];VNY]FN:W>]A=?KNV_Z;WL=[]IU?^IV^]WN43<>'P19;Q+T*GB-
M5"^8FS%,Z0$]$.:S@/@4S?6D/Z,Q"SIH2"F:J5X2S;#$8H?#SLN8%%;0IWH9
MJ21]&6QPY$]XD.$-K*/UI$M!.URL':_;[3E?>U4JU#=;RVSUD^UZ=L_MI#*T
M$.P&D]G<?V,2+4]+^GTO4[O7U]=.UOI5*HE)",.ZSN?'R3Q;IPT[E(!KV+J]
M0NC%#L$IGN$54I^?9N/"(&LL.,NV4GGONH"8^"EG/#HX2N^,.)PP0,A&V@B\
M&EC0A]E:KM;^8T&4'&(\L"2)8HHMYQM&+&"K6))M@SIHN5S-\@^0$I*H_J>#
M%V%PFF 6XC S1?-0'A1$5!T1?K)6Q24!+-M%B8/.FN^<$).,35UD1F0FP)<_
M,[3A4B;"#Q(]$O67F ZL<KM3-XZ^C1<PHH&FT%P[S!"F"M5T#]1?&VB*[8UY
M,\6"\/">A>K!=<:DHJYVO'L&)_OP0"A^VD;+;^?]B*PD:0AJAM=$G6"6//F1
MR3*CK"&X$6R5\.D8;O?T(SY4TIWJ&L);^.DXA*G)BKR\D"[L;I6^(5QXVW(1
M<Y%-/8?'*Q[Q+1AW&/&P>N?/]VH(?1B&\$Z0^0>\$[!;"6S2_FN8WG=@>@UC
MCN#R62SXGEV"/%(VBYB=MV<Q%7Q'5!QT@?-4WBSLE$.T1O\@\=G[R2BN'53M
MX!"B^@JT0G/M,"I^I],-9]6OPY*D=JC?!4D@L!SQ*-JR_/DL#61F7>UXD#61
M@"20#C["&1>02!G8#*+:P:8"*R\@6<59^*EB<_&\6AFW]8RX:="QE%LLO@NW
MW*7^;<?!%@[<P?66"Y4<F3;]5%([U$+XJBXQ/T1+;CJ&Q?;&/+I/@XW/UK@B
MD#7*&GI#W$=8K,&2#X+ODPV<J=AGU>&L65U /4Z1AZ*([8M #PV7I92\6,/(
M%4[L"QC/#C:$AKKW2O#(E.KJV;@A\T1<P-TQL+H6BB''4H8/+(B"MA(H>*QX
MU:,+^.'^$3B<O"R^DB^#RQSZ[QIPD@SG#K@M<J B_\Z=\%KD1#G5STWHM<Z$
MT])";L2;UAE1*F/D3KQMG1.5%9/<D7>M<^1"42;WY9?6^6*L^.1N_/J_&ZJP
ME+MQW58WCNM7.N9J4]AYOE*F'6E3&'JN'*?]:%,P6JSZ:0?:%(F62XW:A3:%
MH16U36U%F^)04QU5^]"FZ/-<V5;[T::H\W)U6+O2INBS7'[6+K0IZCRI=^NJ
M5IMB37.-73O1OABSHJ"O#:DKR+QQ2GY ,OCE]BIO4'_4?R3>_@502P,$%
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MI>54Y>O F7%=SK)*D=##:,*8W"/R(-D%^_A^$H6A"AJ8A8KZ06V=TO<U^K"
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MSCO!F<QEA,DD_ )+QP"QE((XWT613].:)IF5]&8;7D9%JBBP+58RS>]09O
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ML%Z-#\^'9%*96,.47,JXU&& "CB9 7N?__EFOW922!GFK,"RV;M\OV^J\YB
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M#K\J_WVX0Y!A;7'3Q?4.:HM?3(]V,)FN9>PW/D3H!1B;0$2J-W"' [?=ZVW
M+MB%RZ3S#!S[] ;+714%'R<:<]6,]ZWB=L#G)=V2@WZK=(B%!W1"N7))T5S&
M/D056H@2 TN)24&)H$+ZRFC+-D@7)S5I;=XQ.O-0/1U&L?G(/S;QV/::W23+
M@;YZA9?\%V5I_@_PS]BL]+/"58L34[K%'0QZ6(C2IN"18]>3&3Z)3E54:JE<
M5+G"W*4"JA\JWVB'!GJJ4UO5*:70WUB-87^PM2.QI_?-.'B"BQ>=1@<V=:^2
MY?(WINM*Z;7%5C,25&KQFPPS=,!B,Y5CF"*?PXP'2KM6:##D_AP;/&ZKL=12
M;Z,L]I39MUF&\27;BCU4% )/ E (3RBTU7=M32X\= R6R,;&3)EJWP^4+839
MI87E*ZL;.G@6>7@T!9EKKRR3A8[<H0ZP+B:&EHQ&6!2,#)V*FN]%6>#;6 F$
M9SU0'%;M)YZ<F?S'A<APG..WD]_U&C\[+ONJ=IXE?"H34I* K/57-$8@-C(J
M2^)8 Q &73UFGF9@0*0*8R>;^:;6,4(/_H)QD%+PF@*_GBJ%A@\.J]>ME6Y;
M3)\?(C+J9825BXH21#HU)7E*MR/5PF_3L&O&Q8*MJ8R+5%EXEX@<ZQG-ZP/D
M(RS54EI$?$DLU20"S&9!C@QE.\:\6-J7YD4S_]T47YW(8%1K*R3%1^K.@5L^
MR8 <X[S D[QUZ-,O^6^V'FUU9,2)FY7G 9M'\@^1&OTB>00/);I2<*(+95%P
MI-4#T=:*YDL+A94"F854V&\1E]>=1?>8$QY9I]GTH^$4A@T[QDTYGEU0G/=N
MUDO0BL#%BSA,[Y/!''V,1H"B[G2S1@(7':Z TV<S"AE8J!S:KM1ISPLHJAL4
M)<80+GVNU2)[H)'',J_88@9^U6LMCY0KE50+=20]HZF9\-I<72[6F$<J)!EV
M)*2[=NPT"$!<ZK18E&L-4*7"=99:YE)E6U*U&F-IZO#6BDB66B:)U&4I>D>A
M1ZSXF^I@M4)[H]?I1>2KIK*UJVOZYD5R4*%?KNB[4,G7]#;*Z^!^\X#=UF+)
M6%IZKH'J>@KGTAV$KZ;8?I(BI=>G@N*0^8@+H:*U2I@V\GU%Z([I[ JCP)&:
MJOX50Y#&1;,$VV%6K$ZL69DXU0:9ZZU)"F]);GL"*^]3*U:$OD7]T+8%((RB
M97@RM,U)L6!F6;.(#DMC+SF!9Q^;YN"64B+3Q(KHX>XEKIG_#FMSW:K+Q@>F
MYNKU1-'Y5ND7,Z=Q[X179&25[63/_^?]VX8[$&"Z #)HKVC2"E]^SD!OEJ^_
M?(W1X*=2.:!6I_: QD$TQ%X*\'%D7ZP8G(!-<3;+#4>Z,2J.S70YQFLB1&(]
M1?199!)#+ F"U@8E=N=_ /)36PD\+2P:6TQ7-!4MHO]M==,:"S"57?,CLGU4
M81T4")3W;J@3B0_G.[>F,+UE%VZ7G9C#\(L>JH]SY.;JJKY4TWXUC_0H8Z7*
M2"B%G%AZV!9'>9/\2^+-:(<[1)P!VHH9]7-&[H/OU7O5FXI(16E=#VR/0(5C
MPYJBF+H0VZP78Z L^QQ&%/\6DK\![5DKIW(G!  (58K$6>>$L 7&8#ZRK2-!
M$E<.X4!,:=P<I)5U2F,1FGZ-*I[:5/P\DJ9JS=?%1$37G;BFN1A*D-24>((L
M*@A*VJ0,F=R\QE8?MA1NOA)=JW)0X;.^Y>3DX:+-&2CI*+,6^GH&6];NK6[4
M6I+'5&$WGQ_79TD@1P/<AD&-@JOA-6[9BWFH0H6:#<E'&'2D@P4",FNG?BQ9
M:,KCXW)@ZM'*K1LF"@=9.8#D%DE#'9KRB^^<DG,7$3IEJ-2"$=CWJ)I@*:YZ
M/6VFA@6/:\(=#R+!Q"*,KI2H/279D,H'4-7I,J7!DS.=DEPK<;\(9C0-LDO$
MND_YZ9PD*MSGP2AC<B=EQ-B6)K:MI\M-UD-R*2,L]U?@C$*/%O&47)X637,2
MUW&E#=!2["D2C*X)+%P'_'\D=9!1>^TX9[]4T*+*E!"5L]G, +6B<OZ)SF2S
MM06JCO/VT_6]Y6(IL6$.ANZG>-AQA?!AK7_4A6L>4&INGQN@1I=)<FX[[Y2T
M3- YZ<$WJ.]$P]1Z[:0/L"!%#)U+"\J9I=L*OYA7(_[69?0Y!G;>1*LK<U*F
M(I=U)N4@R6T2V.77^B[?O3TQFKV!OUJL#[[@I#(=%J*E3:]8OMWFQ##(!%2=
M0,;Y-0!]MWAV;=!P@D7QC0H;,"*,"$; 6=^W<1)K<J2B9[D,B,1FHRBUZZ$F
M3E']HXRG7%!(2J^Z86+X<&5<<F<KF4YRDD2.8C5&XT"V^B2^G!LY=?:[9"&B
M9Q>W1H%'" ]9C:+)N00 ;;IX*ABN1,'?16C\BDV;UNYH,ALP7).CW0J8YQ'E
M81W[5AJMN:&9V[F^U5"0K$R'OV^PFLDLB1;4YD*1JC+-FG:[L"DK%'(&;YFJ
M,3N0HQD"S%,5Z'SM54]Q^8$3OSKH55L5DMF-E(WU_9OB9'5>G2T+22>XUDHP
M&G?Q/CWFK'AF1'<CN2U$^/"]UI IYK?6&J/KM^(J$9Y?(+=J!P?#6$%1-L'[
M]&4UH[9R_8>/G]Z CHJM5MZ Z+6N?]/:AZXUJ7O$N+AI_(R\ZYW9=W'52)@:
M).J:A%)AVU769)=29<(+.[!%<*G))=VPP3+>X7V2VVK\=W'+:I]JF)9ZOV6@
M]->ZZ5D=;L741>VKIO@2^AFEJ6AJRY%,"'(H7H!.*!^?F/)Z<.0,"82U_(I%
M&>>8G6+1$J^G\)<Y 0VO;9W2RB(;B- K2;*I-?@J"M<=:$ <D*#5%/;^619:
M"5E5@;S.+Y&P'4\@]30A[38:!OE-+Z"CN47#Z6[W E#V#'4MR8^V0DQ.SIY0
M@]2QETV1_7B<),*.Y6<( SK+O8)E [V/8+P SC(V,C8^0U<H$RP2F"Y'2_)Z
MH<H["86B4Y0MI6U$/;;3B\WG),,1R>O]2W1>?=&TW,LU[SO[Q2VUAGN4QF^D
MZM_:\8U4H7+=MZZYWINEB.BAJ*IBPQ75T[  W*FB:*Q$@[ EW7)L=%@Z4S)V
M.3* N=FF'PU'!FS8,6[*\>R"R"S9=M5D-WT1;Y.%Z-52X42:]"L;LIH+6R-O
MR$F45CXLO>0@(M"C:&KXV )4B_*ZUG?1>BZQE('YS3IX*I&D"Q95+M@+7Q#6
M1D[U:%X1<&D,1FVRPK;/K_.,Y+-%G8WTK3=P=?(.KL\EQ_V(>NOB0/ 8Q5'@
M_88M(4&F?4!FIW%;%F$,>)VF8H(XSI<;^^9TDU(;PA/0R2H-9TG@"Q,RDGMQ
M8$J'5B;-345Q0>Y8W[@R12G@*3L V?/EL-7U5?LWKL3(/(=/A7"<L327?WDD
M-=Z  (;EZ&84DM6]2G*L,^X8@^N5/KH4DUFHF+#(%<=1,]<1V2-TC]#<-"HY
M#-=B'.L:+ :>H=UX@;VIZ;Q*=T:,C;N!C<^OLK'FNV&:;ZOSE\X'N^JI>+N]
ME[^>?CX_$V_./W\Z_WQR^?[\[-&8'1_V+V_.S]Z>GEV<OH4#/[LX__#^[<DE
M_'%Q"?]\/#V[O!#G[\3YIU,#B0L&Q>.!8N]+*#,?^Y_L;^HQ?X<0ZS^N>#=J
M40YO"JRBM6!>9>N8OFT$<AYE*8QVH_QC,[+;HN.S+P B4);?48+F-9AE1NK!
MZ(5XQ/Q18R<?Y4_;A^ IOS@+&KS;;O;ZG9]HR:F_YJ%V\^"P?<<S+HA+=W#'
M0YUF?W"X40-]Y];@EWCQV"WB'A 2+9_W794Y +Q&ISDRF@U^L)K$9V@>A^,&
M8CCB_:$.CZ]43!5Z+/(;HBB>)%4D?Q2VL8Y(<^PG:CBX%Y$^-8T>/!Z-UE$
M@ 2+"/_Q0_>'C0/ABB/<%) ^FW1[.,2XG& 9SX\1Q3:>8LA*1<8QDC"24-P"
M9B[<A2,L)EA,, ?8  Y ,_O*B\S-Q9&)W8/]/ K*7*A9JJ9#A:W*'98=C#D/
MASDL41Y-HCS)?<NWHXIY%Y=X1.'WWGJGS'L,2(^R!*L%.7CEC)'&R82"\TV$
MN?T+,T_V[V9,;69,S)@,;F&H/B,,(\RW((S+",,(PQR&$>9I.4Q5169E>%?<
M*TSX?YWP&:@,5 8J Y6!^E*!RN[#E^8^7(<CG[$(0*:2([:Y7@CM,U 9J Q4
M!BH#E56O!U*].LT^JU[?C",?M(?9O&*D;"VO.)K+ "M[K=7%-@TA5A+<IK"
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+ $$!   V3P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
